BACKGROUND: Field cancerization denotes the occurrence of molecular alterations in histologically normal tissues adjacent to tumors. In prostate cancer, identification of field cancerization has several potential clinical applications. However, prostate field cancerization remains ill defined. Our previous work has shown up-regulated mRNA of the transcription factor early growth response 1 (EGR-1) and the lipogenic enzyme fatty acid synthase (FAS) in tissues adjacent to prostate cancer. METHODS: Immunofluorescence data were analyzed quantitatively by spectral imaging and linear unmixing to determine the protein expression levels of EGR-1 and FAS in human cancerous, histologically normal adjacent, and disease-free prostate tissues. RESULTS: EGR-1 expression was elevated in both structurally intact tumor adjacent (1.6× on average) and in tumor (3.0× on average) tissues compared to disease-free tissues. In addition, the ratio of cytoplasmic versus nuclear EGR-1 expression was elevated in both tumor adjacent and tumor tissues. Similarly, FAS expression was elevated in both tumor adjacent (2.7× on average) and in tumor (2.5× on average) compared to disease-free tissues. CONCLUSIONS: EGR-1 and FAS expression is similarly deregulated in tumor and structurally intact adjacent prostate tissues and defines field cancerization. In cases with high suspicion of prostate cancer but negative biopsy, identification of field cancerization could help clinicians target areas for repeat biopsy. Field cancerization at surgical margins on prostatectomy specimen should also be looked at as a predictor of cancer recurrence. EGR-1 and FAS could also serve as molecular targets for chemoprevention.
BACKGROUND: Field cancerization denotes the occurrence of molecular alterations in histologically normal tissues adjacent to tumors. In prostate cancer, identification of field cancerization has several potential clinical applications. However, prostate field cancerization remains ill defined. Our previous work has shown up-regulated mRNA of the transcription factor early growth response 1 (EGR-1) and the lipogenic enzyme fatty acid synthase (FAS) in tissues adjacent to prostate cancer. METHODS: Immunofluorescence data were analyzed quantitatively by spectral imaging and linear unmixing to determine the protein expression levels of EGR-1 and FAS in humancancerous, histologically normal adjacent, and disease-free prostate tissues. RESULTS:EGR-1 expression was elevated in both structurally intact tumor adjacent (1.6× on average) and in tumor (3.0× on average) tissues compared to disease-free tissues. In addition, the ratio of cytoplasmic versus nuclear EGR-1 expression was elevated in both tumor adjacent and tumor tissues. Similarly, FAS expression was elevated in both tumor adjacent (2.7× on average) and in tumor (2.5× on average) compared to disease-free tissues. CONCLUSIONS:EGR-1 and FAS expression is similarly deregulated in tumor and structurally intact adjacent prostate tissues and defines field cancerization. In cases with high suspicion of prostate cancer but negative biopsy, identification of field cancerization could help clinicians target areas for repeat biopsy. Field cancerization at surgical margins on prostatectomy specimen should also be looked at as a predictor of cancer recurrence. EGR-1 and FAS could also serve as molecular targets for chemoprevention.
Authors: Uzma S Shah; Rajiv Dhir; Susanne M Gollin; Uma R Chandran; Dale Lewis; Marie Acquafondata; Beth R Pflug Journal: Hum Pathol Date: 2006-02-07 Impact factor: 3.466
Authors: Kai-Hsiung Chang; Rui Li; Mahboubeh Papari-Zareei; Lori Watumull; Yan Daniel Zhao; Richard J Auchus; Nima Sharifi Journal: Proc Natl Acad Sci U S A Date: 2011-07-27 Impact factor: 11.205
Authors: Michelangelo Fiorentino; Giorgia Zadra; Emanuele Palescandolo; Giuseppe Fedele; Dyane Bailey; Christopher Fiore; Paul L Nguyen; Toshiro Migita; Raffaella Zamponi; Dolores Di Vizio; Carmen Priolo; Chandan Sharma; Wanling Xie; Martin E Hemler; Lorelei Mucci; Edward Giovannucci; Stephen Finn; Massimo Loda Journal: Lab Invest Date: 2008-10-06 Impact factor: 5.662
Authors: Gloria R Mora; Kenneth R Olivier; John C Cheville; Richard F Mitchell; Wilma L Lingle; Donald J Tindall Journal: Mol Cancer Res Date: 2004-02 Impact factor: 5.852
Authors: Ying Zhang; Thomas Perez; Beth Blondin; Jing Du; Ping Liu; Diana Escarzaga; John S Coon; Larry E Morrison; Katerina Pestova Journal: BMC Cancer Date: 2014-02-25 Impact factor: 4.430
Authors: Kristin N Gabriel; Anna C Jones; Julie P T Nguyen; Kresta S Antillon; Sara N Janos; Heidi N Overton; Shannon M Jenkins; Emily H Frisch; Kristina A Trujillo; Marco Bisoffi Journal: Int J Oncol Date: 2016-08-22 Impact factor: 5.650
Authors: Ayesha N Shajahan-Haq; Simina M Boca; Lu Jin; Krithika Bhuvaneshwar; Yuriy Gusev; Amrita K Cheema; Diane D Demas; Kristopher S Raghavan; Ryan Michalek; Subha Madhavan; Robert Clarke Journal: Oncotarget Date: 2017-05-30
Authors: Anna C Jones; Kresta S Antillon; Shannon M Jenkins; Sara N Janos; Heidi N Overton; Dor S Shoshan; Edgar G Fischer; Kristina A Trujillo; Marco Bisoffi Journal: PLoS One Date: 2015-03-13 Impact factor: 3.240